38 Sidney Street
>Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
August 7, 2007
Founders: Lewis Cantley, Tak Mak, Craig Thompson, Shin-San Michael Su
CEO: David Schenkein
CMO (Medical): Chris Bowden
CSO (Scientific): Scott Biller
Please click here for Agios job opportunities.
Please click here for clinical trial information.